New data from analysts at SSR show list prices haven't been growing as fast as they were—and the amount payers actually shell out is falling. 

Keytruda-Lenvima combo wins simultaneous OKs. Eisai and Biogen ditch second BACE drug. Sanofi is leaving Bangladesh. Henlius raises $410 million.

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

Novartis has gotten out in front of an FDA, and its competitors, by halting worldwide distribution of its generic Zantac.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.

It's official: Pharma faces an aggressive plan for price negotiation on top brands, price-hike rollbacks and more. But does the bill stand a chance?

Months after the FDA demanded Lupin act on failures at an Indian plant, the drugmaker may have known a reckoning was coming. They were right.

Roche has spent years reprioritizing its manufacturing spending, and as part of that process, it's exiting a small molecule site in Ireland.